Issue Date: October 3, 2016
Amgen licenses RNAi drugs from Arrowhead
Amgen has licensed RNAi drug and subcutaneous drug delivery technology from Arrowhead Pharmaceuticals for cardiovascular disease. The big biotech firm will pay Arrowhead $35 million up front, $22 million in an equity investment, and up to $617 million in option and milestone payments. The deal includes Arrowhead’s RNAi ARC-LPA program, which brings molecules designed to reduce elevated lipoprotein(a), a risk factor for heart disease.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society